1-(1-吡咯烷)-2-丙胺 | 50998-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(1-吡咯烷)-2-丙胺
• 英文名称: 1H-pyrrole-1-ethanamine, tetrahydro-alpha-methyl-
• 英文别名: 1-pyrrolidin-1-ylpropan-2-amine；1-methyl-2-pyrrolidin-1-yl-ethylamine；n-(2-aminopropyl)pyrrolidine；1-(2-aminopropyl)pyrrolidine；1-(Pyrrolidin-1-yl)propan-2-amine
• CAS: 50998-03-3
• 化学式: C₇H₁₆N₂
• mdl: MFCD01318919
• 分子量: 128.217
• InChiKey: ZLGZKMHJXLDWSP-UHFFFAOYSA-N

物化性质

• 沸点：
  181.8±8.0 °C(Predicted)
• 密度：
  0.929±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H318
• 危险性防范说明：
  P280,P305 + P351 + P338

反应信息

• 作为反应物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 、 1-(1-吡咯烷)-2-丙胺 以 乙醇 为溶剂， 反应 0.25h， 以24%的产率得到1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(1-(pyrrolidin-1-yl)propan-2-ylamino)ethanol
  参考文献：
  名称：

  Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against Plasmodium falciparum

  摘要：

  A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.

  DOI：

  10.1021/jm200647u
• 作为产物：
  描述：

  四氢吡咯 、 2-amino-1-bromopropane hydrobromide 在 potassium carbonate 作用下， 生成 1-(1-吡咯烷)-2-丙胺
  参考文献：
  名称：

  Chechik, V. O.; Bobylev, V. A., Russian Journal of General Chemistry, 1994, vol. 64, # 10.2, p. 1501 - 1502

  摘要：

  DOI：

文献信息

• [EN] N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROCYCLYL ET HÉTÉROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE SERVANT D'AGONISTES DE SSTR4
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021202775A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 and X12 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

  披露了公式（1）的化合物，以及其中n、R1、R4、R5、R6、R7、R8、R9、R10、R11、R14、X2、X3和X12在说明书中定义的药用可接受盐。本公开还涉及用于制备公式（1）化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与SSTR4相关的疾病、障碍和状况。
• INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20200055874A1

  公开（公告）日：2020-02-20

  Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

  Sultam化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与KEAP1-Nrf2相互作用相关的疾病状态、疾病和病况的方法，如炎症性肠病，包括克罗恩病和溃疡性结肠炎。
• Novel compounds
  申请人：——

  公开号：US20040053943A1

  公开（公告）日：2004-03-18

  The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.

  本发明涉及一种用于治疗哺乳动物疾病的新化合物，其化学式为（I），其中发生了不恰当、过度或不良的血管生成以及/或发生了过度的Tie2受体活性。
• [EN] METHODS FOR THE MONO-AMIDATION OF PHOSPHATES AND PHOSPHONATES<br/>[FR] PROCÉDÉS POUR LA MONO-AMIDATION DE PHOSPHATES ET DE PHOSPHONATES
  申请人：UNIV TEXAS

  公开号：WO2021202886A1

  公开（公告）日：2021-10-07

  Provided is a method for the preparation of mono-amidated phosphates or phosphonates as well as mono-amidated phosphates and phosphonates prepared by such method.

  提供了一种制备单酰胺磷酸盐或膦酸盐的方法，以及通过该方法制备的单酰胺磷酸盐和膦酸盐。
• Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Tung S. Jay

  公开号：US20050020659A1

  公开（公告）日：2005-01-27

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了一种布雷肯肽B1受体拮抗剂化合物，可用于治疗哺乳动物中由布雷肯肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计也会表现出增强的作用持续时间。